ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the C...
Akzo's 4Q25 results were roughly in line with previous quarters, with weak volumes and negative FX leading to a slight decline in adjusted EBITDA, despite sizeable efficiency improvement initiatives. 2026 is expected to bring more of the same, with Akzo forecasting flat volumes and an FY26 adjusted EBITDA that is guided to be up at least 2% (or at least 7% excluding negative FX and scope effects). With current efficiency improvement initiatives expected to have mostly run their course in 2027, t...
Aalberts: Preview: Another quarter in no man's land? / Ahold Delhaize: Confirms the acquisition of Delfood / AGEAS: China – state to inject capital into insurers / AkzoNobel: Tepid 4Q25 results and FY26 outlook / D'Ieteren: Belgian car registrations down 19%, 65% of 2019 level, VW down only 5% / Xior Student Housing: Sound organic trends continue, two-year guidance revealed
4Q adjusted EBITDA dropped by 4% y/y and was in line with our forecast while being 2% below consensus. Akzo guides for a FY26 adj EBITDA at or above € 1.47bn, which is at the low end 2% below our forecast and 4% below consensus. The merger with Axalta is expected to close in late 2026 or early 2027. Taking into account the volatile track record and low structural growth, we maintain our Hold rating and € 65 target price.
Exor Press Release - 2026 Corporate Calendar Amsterdam, 30 January 2026 EXOR PUBLISHES ITS 2026 CORPORATE CALENDAR Exor N.V. announced today the following corporate calendar for 2026: 23 March 2026: Publication of the financial statements for the full year 202524 March 2026: Investor & Analyst Call20 May 2026: Annual General Meeting of Shareholders22 September 2026: Publication of the interim financial statements for the half year 2026 The 2026 corporate calendar will be available on Exor’s website under the section. Any changes will be disclosed to the market on a timely basis. ...
Eurocommercial Properties: 19% stock dividend take up, refinancing completion and leasing update; Ontex: 2H25 consensus release; Signify: 4Q25 results; prepare for a reset; Staffing Sector: Manpower; 4Q25 beat on better revenue trends, 1Q26 outlook positive; WDP: 2030 ambitions revealed, Italy and Spain to come
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.